Evaluation of Fisetin to Reduce Systemic Senescence
Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study
This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, randomized clinical trial designed to examine the effect of two different Fisetin dosing schedules on peripheral blood cells and biomarkers related to aging as well as the occurrence of side effects. The purpose of this study is to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood. 96 healthy volunteers will be randomized into one of two arms (1:1). Group 1 - n= 48: Fisetin Daily Dosing; Group 2 - n=48: Fisetin Bolus Dosing.
Studietype
Studietype
Registrering (Faktiske)
Registrering
Fase
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Colorado
-
Vail, Colorado, Forente stater, 81657
- Steadman Philippon Research Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults ≥55 years of age;
- Capacity to personally give informed consent (consent via legally authorized representative will not be accepted);
- Willing to comply with all study procedures and assessments.
Exclusion Criteria:
-
Within 2 years of signing informed consent history of active blood disorders (i.e., DVTs, chronic blood clotting, hemophilia, leukemia, myeloma, etc.); or active malignancy of any type or history of a malignancy (with the exception of Subjects with a history of treated basal or squamous cell carcinoma);
-
Females who are nursing a child, are pregnant, or are planning to become pregnant during drug dosing;
-
Males who do not wish to abstain from sex with women of childbearing potential without use of contraceptive protection by either party during drug dosing;
-
Any significant illness within the last 30 days requiring clinical care, and/or any medications, medical condition, including findings in medical history or in the baseline assessments that, in the opinion of the Principal Clinical Investigator or the screening clinician, constitutes a risk or contraindication for participation in the study or that could interfere with the study conduct, endpoint evaluation, or prevent the subject from fully participating in all aspects of the study;
-
Allergy to any active or inactive ingredient of Fisetin, and/or taking medication with known Fisetin interaction;
-
Subjects with any of the following drug/medication statuses:
- Taking medications that affect insulin activity, including Metformin or Acarbose, within one week of signing informed consent;
- Currently taking Warfarin or related anticoagulants;
- Currently taking Lithium;
- Senolytic agents taken within the past 3 months and are not willing to discontinue these medications through the duration of the study, including: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax;
- Taking drugs that induce significant cellular stress and are not willing to discontinue these medications through the duration of the study, including alkylating agents, anthracyclines, platins, and other chemotherapy drugs;
- Taking the following drugs if they cannot be held (per the Principal Investigator) for at least 2 days before and during administration of Fisetin: cyclosporine, tacrolimus, repaglinide, and bosentan;
- Taking a glucocorticoid within 1 month of signing informed consent;
- Currently taking phenytoin or nateglinide;
-
PHQ-9 - Patient Health Questionnaire - total score exceeds 9;
-
Inability to tolerate oral medication;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Fisetin (daily dosing)
A single Fisetin 100mg capsule will be taken daily for 60 days. |
Oral Fisetin 100mg capsule
Andre navn:
|
|
Eksperimentell: Fisetin (bolus dosing)
Fisetin 100 mg capsules (~20 mg/ kg/ day) will be administered orally for two consecutive days (days 1 and 2) followed by 28 days off. This cycle of 2 dosing days followed by 28 days off will repeat for a total of 2 cycles, or 4 dosing days total. Dosing days will occur on days 1&2, and 31&32. |
Oral Fisetin 100mg capsule, dosed at 20 mg/kg
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Tidsramme: Baseline, Visit 4 (45 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 4 (45 days)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)
Tidsramme: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 5 (60 days)
|
|
Change from baseline in senescence-related serum biomarkers
Tidsramme: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Concentrations of proteins related to senescence will be analyzed using multiplex immunoassays and ELISA from serum/plasma. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Number of participants experiencing one or more treatment-emergent adverse events
Tidsramme: From date of study drug dosing until the end of the study, an average of 2 months
|
Number of participants experiencing one or more treatment-emergent adverse events |
From date of study drug dosing until the end of the study, an average of 2 months
|
|
Perturbations in senescent PBMC values
Tidsramme: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Cell types measured via flow cytometry and analyzed via immunophenotype and senescent panels. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
|
Perturbations in senescent serum/plasma biomarkers values
Tidsramme: Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
The variability over visits of serum/plasma concentrations of proteins related to senescence will be assessed using multiplex immunoassay and ELISA. |
Baseline, Visit 2 (15 days), Visit 3 (35 days), Visit 4 (45 days), Visit 5 (60 days)
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Hovedetterforsker: Johnny Huard, PhD, Steadman Philippon Research Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 2022-154
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .